People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lumen Bioscience, Inc. | — | Biotechnology | Series C | $150.9M | $154.0M | 2022 |
Mark Litton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Litton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Erik Anderson | 1 | 12 |
| ROBERT CARLSON | 1 | 4 |
| John Morrow | 1 | 4 |
| James Roberts | 1 | 3 |
| Marcos Milla | 1 | 2 |
| Ed Schlect | 1 | 2 |
| Don Schlosser | 1 | 1 |
| Eric Orse | 1 | 1 |
| Craig Behnke | 1 | 1 |
| Brian Finrow | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.